par Bense, Rico RD;Sotiriou, Christos 
;Piccart-Gebhart, Martine ;Haanen, John B A G JB;van Vugt, Marcel A T M MA;de Vries, Elisabeth Ge E Liesbeth E.;Schröder, Carolien P;Fehrmann, Rudolf RS
Référence Journal of the National Cancer Institute, 109, 1
Publication Publié, 2016-10-13
;Piccart-Gebhart, Martine ;Haanen, John B A G JB;van Vugt, Marcel A T M MA;de Vries, Elisabeth Ge E Liesbeth E.;Schröder, Carolien P;Fehrmann, Rudolf RSRéférence Journal of the National Cancer Institute, 109, 1
Publication Publié, 2016-10-13
Article révisé par les pairs
| Résumé : | Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting in considerable undertreatment or overtreatment. New insights into the role of tumor-infiltrating immune cells suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options such as immunotherapy. |
